/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos · Oct 7, 2026

Experts discuss managing HER2+ gynecologic cancers with T-DXd, focusing on ILD surveillance, toxicity mitigation, and ADC sequencing.

Clinicians Re-Challenge Grade 1 TDXD-Induced ILD But Strictly Avoid Grade 2

While oncologists feel comfortable re-challenging patients after grade 1 asymptomatic radiographic pneumonitis resolves—monitoring them closely with six-week CT scans—they refuse to restart trastuzumab deruxtecan following grade 2 ILD. Current clinical literature lacks sufficient safety evidence to justify retreating grade 2 toxicity, leading clinicians to draw a strict line against restarting therapy.

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·a month ago

Rapid Pulmonology Consultations Prevent Premature ADC Discontinuation by Ruling Out Mimics

Suspected interstitial lung disease on chest imaging can closely resemble infectious conditions like pneumonia. Involving pulmonary specialists early for inpatient evaluation, viral testing, or bronchoscopy prevents physicians from unnecessarily stopping effective trastuzumab deruxtecan therapy for a misdiagnosed toxicity, while ensuring true pulmonary complications receive rapid steroid or antibiotic intervention.

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·a month ago

Consecutive Topoisomerase-1 Payload ADCs Risk Cross-Resistance Across Gynecologic Cancers

When sequencing antibody-drug conjugates, switching payloads reduces cross-resistance risk, and emerging evidence shows sequential activity even when targeting the same receptor with distinct payloads. However, clinicians express major concern that sequencing one topoisomerase-1 payload ADC after another could attenuate the second drug's activity, making the initial payload choice critical across gynecologic malignancies.

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·a month ago

Nine-Week Chest CTs and Three-Month Echocardiograms Anchor TDXD Toxicity Surveillance

Faculty consensus establishes chest CT surveillance every nine weeks for patients receiving trastuzumab deruxtecan, narrowing to six-week intervals for higher-risk patients or during ILD re-challenge. For cardiac monitoring, clinicians obtain a baseline echocardiogram followed by repeat evaluations at least every three months to catch asymptomatic declines in left ventricular ejection fraction.

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·a month ago

Prioritize Mirvetuximab Over TDXD in Ovarian Cancer to Preserve Proven Survival Benefits

When selecting initial ADC therapy for ovarian cancer patients with dual biomarker expression (FR-alpha positive and HER2-positive), clinicians favor starting with mirvetuximab soravtansine over trastuzumab deruxtecan. Initiating mirvetuximab captures its proven overall survival advantage while keeping trastuzumab deruxtecan available as an effective option for subsequent sequencing.

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·a month ago